Publications
Publications
58. Discovery of CA9–005 as a new carbonic anhydrase 9 inhibitor using a DNA encoded-libraries
Lee, J. H.; Park, S. B.; Koh, B.; Kim, J.; Choi, K. J.; Im, J.; Lim, B.; Kim, D.; Lee, B.; Yu, S.; Cho, N. -C.; Kim, D.*; Lee, Y.*; Kim, H. J.*; Kim, K. Y.*; Heo, J. -N*
Results Chem. 2025, 16, 102455.
57. Calcium(II)-catalyzed [2+3] annulation of enynones: a sustainablem approach to 9H-pyrrolo[1,2-a]indole frameworks
Kale, A.; Rivonker, S. C.; Kim. J.-h.; Hwang, J. Y.; Choi, Y.; Lee, K.*
56. Discovery of a novel molecular glue degrader targeting GSPT1/2 with a non-IMiD-based CRBN binder
Park, S.; Takwale, A. D.; Lee, J.-E.; Yu, N.; Kim, Y. H.; Lee, J. Y.; Cho, Y. H.; Cho, J. H.; Moon, J. H.; Lee, G.; Kim, J.-A.; Hwang, J. Y.*; Kim, J.-H.*
55. Copper-Mediated Three-Component Reaction for the Synthesis of N-Sulfonylamidine on DNA
Kwon, T. Y.; Lee, Y.; Cho, K.-J.; Kim, H. J.*
54. Discovery of novel benzosultam CRBN ligands
Park, H.; Raikar, S. S.; Kim, Y.; Chae, C. H.; Cho, Y.-H.; Kim, P.*
53. Discovery of novel WRN inhibitors for treating MSI-H colorectal cancers
Moon, B.; Go, A.; Park, S.; Kim, H. J.; An, D.; Kim, J.; Lee, J.-Y.; Kim, J.-H.*; Hwang, J. Y.*; Kim, J.-A.*
52. Photoredox-Catalyzed Minisci-Type Acylation of Heterocyclic C-H Bonds with Amino Acid-Tethered Dihydropyridines
Yang, H.; Shin, H.; Lee, Y.; Lim, D.; Kwon, N. Y.; Rakshit, A.; Singh, P.; Kim, H. J.*; Moon, K.; Kim, I. S.*
51. Design and evaluation of anaplastic lymphoma kinase degraders using a covalent fumarate handle
Yu, N.; Lee, J.-E.; Park, S.; Yun, S. K.; Ryu, D. H.; Kim, J.-A.*; Kim, J.-H.*; Hwang, J. Y.*
50. Palladium-Catalyzed Amination of Aryl Halides with Aqueous Ammonia and Hydroxide Base Enabled by Ligand Development
Choi, K.; Brunn, J. N.; Borate, K.; Kaduskar, R.; Pueyo, C. L.; Shinde, H.; Goetz, R.; Hartwig, J. F.*
49. Antitrypanosomal Chloronitrobenzamides
Carrillo, A. K.; Kadayat, T. M.; Hwang, J. Y.; Chen, Y.; Zhu, F.; Holbrook, G.; Gillingwater, K.; Connelly, M. C.; Yang, L.; Kaiser, M.; Guy, R. K.*
48. A single-step synthesis of 5,6-dihydropyrrolo[2,1-a] isoquinolines and evaluation of their anti-leukemic activity
Park, H.; Raikar, S. S.; Ahn, M. J.; Kim. S. H.; Kim, P.*
47. Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation
Ahn, M. J.; Kim, E. H.; Choi, Y.; Chae. C. H.; Kim, P.*; Kim, S. H.*
46. Development for a new 5-lipoxygenase inhibitors of N-((6-(substituted-amino)-2-methyl-2H-chromen-2-yl)methyl)- N-methyl benzenesulfonamide derivatives
Kim, Y.-C.; Abdildinova, A.; Shin, Y. J.; Han. D. K.; Hwang, J. Y.; Cheon, H. G.*; Gong, Y.-D.*
45. Discovery of pan-IAP degraders via a CRBN recruiting mechanism
Park, S.; Kim, D.; Lee, W.; Cho. J. H.; Kim, S.; Lee, G. S.; Moon, J. H.; Kim, J.-A.; Ha, J. D.; Kim, J.-H.; Kim, H. J.*
44. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models
Lim, Y. S.; Yoo, S.-M.; Patil, V.; Kim, H. W.; Kim, H.-H.; Suh, B.; Park, J. Y.; Jeong, N.-r.; Park, C. H.; Ryu, J. H.; Lee, B.-H.; Kim, P.; Lee, S. H.
43. Copper-mediated three-component reaction for the synthesis of N-acylsulfonamide on DNA
Eom, S.; Kwon, T.; Lee, D. Y.; Park. C. H.; Kim, H. J.*
42. Structure-activity relationship analysis of novel GSPT1 degraders based on benzotriazinone scaffold and its antitumor effect on xenograft mouse model
Takawale, A. D.; Kim, E. Y.; Jang, Y.; Lee, D. H.; Kim, S.; Choi, Y.; Kim. J. H.; Lee, D. Y..; Kim, Y.; Lee, S. M.; Lee, H. K.; Nam, H. J.; Lee, J. Y.; Cho, J. H.; Moon, J. H.; Lee, G. S.; Kim, J. H.; Park, C. H.; Hwang, J. Y.*
41. Cereblon contributes to cardiac dysfunction by degrading Cav1.2α
Park, N.; Marquez, J.; Pham, T. K.; Ko, T. H.; Youn, J. B.; Kim, M.; Choi, S. H.; Moon, J.; Flores, J.; Ko, K. S.; Rhee, B. D.; Shimizu, I.; Minamino, T.; Ha, J. D.; Hwnag, J. Y.; Yang, S. J.; Park, C.-S.; Kim, H. K.*; Han. J.*
40. Pyrazolo[3,4-d]pyrimidine derivatives as irreversible Bruton’s tyrosine kinase inhibitors
Yeom, H.; Achary, R.; Choi, Y.; Park, C. H.; Lee, J.-Y.; Lee, H. K.; Kim, P.*; Cho, S. Y.*
39. Discovery of harmalanium halides as anti-ovarian cancer agents
Choi, Y.; Ji, S. H.; Patil, V.; Kim, E. H.; Park, H.; Kim, S. H.*; Kim, P.*
38. Transformation of tert-butyl amide directing groups to nitriles in iridium-catalyzed C–H bond functionalizations
Kim, D.; Yoo, H.; Park, M. H; Kim, Y.; Chuang, G. J.; Yoo, K.*; Kim, D.*; Kim, H. J.*; Kim, M.*
37. Photoredox-catalyzed halotrifluoromethylations of alkynes with triethylammonium halides: synthesis of tetrasubstituted alkenes containing CF3 and halogens
Lee, W.; Lee, Y.; Yoo, M.; Han, S. B.*; Kim, H. J.*
36. Ir-catalyzed C−H amidation using carbamoyl azides for the syntheses of unsymmetrical ureas
Yoo, K.; Lee, J.; Park, M. H.; Kim, Y.*; Kim, H. J.*; Kim, M.*
35. A chemical switch system to modulate chimeric antigen receptor (CAR) T cell activity through proteolysis-targeting chimera (PROTAC) technology
Lee, S. M.; Kang, C. H.; Choi, S. U.; Kim, Y.; Hwang, J. Y.; Jeong, H. G.; Park, C. H.*
34. Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation
Go, A.; Jang, J. W.; Lee, W.; Ha, J. D; Kim, H. J.*; Nam, H. J.*
33. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
Takwale, A. D.; Jo, S. H.; Jeon, Y. U.; Kim, H. S.; Shin, C. H.; Lee, H. K.; Ahn, S.; Lee, C. O.; Ha, J. D.*; Kim, J. H.*; Hwang, J. Y.*
32. Therapeutic Efficacy of ABN401, a Highly Potent and selective Met inhibitor, based on diagnostic biomarker test in Met-addicted cancer
Kim, J.; Park, K. E.; Jeong, Y. S.; Kim, Y. M.; Park, H.; Nam, J. H.; Jung, K.; Son, W. S.; Jung, H. S.; Lee, J. H.; Jeong, S. H.; Kim, N. A.; Ha, J. Du; Cho, S. Y.; Choi, Y. La; Chung, S. J.; Choi, J. Y.; Hong, S.; Shin, Y. K.*
31. Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma
Park, S.; Jo, S.-H.; Kim, J.-H.; Kim, S.-Y.; Ha, J. D.; Hwang, J. Y.; Lee, M. Y.; Kang, J. S.; Han, T.; Park, S. G., Kim S. H.; Park, C. B.*; Kim, J. H.*
30. Photoredox/rhodium catalysis in C-H activation for the synthesis of nitrogen containing heterocycles
Kim, H. J.; Fabry, D. C.; Mader, S.; Rueping, M.*
29. Catalytic wacker-type oxidations using visible light photoredox catalysis
Ho, Y. A.; Paffenholz, E.; Kim, H. J.; Orgis, B.; Rueping, M.; Fabry, D. C.*
28. Recent Organic Transformations with Silver Carbonate as a Key External Base and Oxidant
Yoo, K.; Jwa, D. G.; Lee, H. E.; Kim, H. J.*; Kim, C.*; Kim M.*
27. Efficient and rapid synthesis of N-substituted isoquinolin-1-ones under mild conditions: Facile access to doryanine derivatives
Takwale, A. D.; Jeon, Y. U.; Lee, D. H.; Kim, H. J.*; Hwang, J. Y.*
26. Succinct syntheses of methopholine, (±)-homolaudanosine, and (±)-dysoxyline via metal-free one-pot double alkylation on 1-methyl-3,4-dihydroisoquinolines
Achary, R.; Kim, S.; Choi, Y.; Mathi, G. R.; Kim, H. J.*; Hwang, J. Y.*; Kim, P.*
25. A novel cereblon modulator for targeted protein degradation
Kim, S. A.; Go, A.; Jo, S. H.; Park, S. J.; Jeon, Y. U.; Kim, J. E.; Lee, H. K.; Park, C. H.; Lee, C. O.; Park, S. G.; Kim, P.; Park, B. C.; Cho, S. Y.; Kim, S.; Ha, J. D.*; Kim, J. H.*; Hwang, J. Y.*
24. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
Kim, K.; Lee, D. H.; Park, S.; Jo, S. H.; Ku, B.; Park, S. G.; Park, B. C.; Jeon, Y. U.; Ahn, S.; Kang, C. H.; Hwang, D.; Chae, S.; Ha, J. D.; Kim, S.*; Hwang, J. Y.*; Kim, J. H.*
23. Recent developments in visible-light-catalyzed multicomponent trifluoromethylation of unsaturated carbon-Carbon bonds
Oh, E. H.; Kim, H. J.*; Han, S. B.*
22. Grignard-mediated rearrangement of trifluoroacetyl from dihydroisoquinoline enamides to afford tertiary trifluoromethylcarbinols
Achary, R.; Mathi, G. R.; Kim, S.; Hwang, J. Y.; Kim, P.*
21. Design and Synthesis of Novel 2,4-Diamino-5-pyrazol-4-yl Pyrimidine Derivatives as Selective Tyro3 Kinase Inhibitors
Kim, D.; Lee, K. W.; Jung, H.; Kim, M.; Lee, J. Y.; Lee, Y.; Hwang, J. Y.; Min, Y.; Lee, C. H.*; Cho, S. Y.*
20. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Kang, C. H.; Lee, D. H.; Lee, C. O.; Ha, J. D.; Park, C. H.*; Hwang, J. Y.*
19. Design and synthesis of novel 3-(2-Aminopyridin-3-yl)-1,2,4-Triazolo[4,3-b]Pyridazine derivatives as a reversible Bruton’s tyrosine kinase inhibitors
Kim, D.; Jung, H.; Jeon, J. H.; Achary, R.; Lee, J. Y.; Kim, P.; Jung, H.; Hwang, J. Y.; Ryu, D. H.; Ha, J. D.; Cho, S. Y.*; Park, C. H.*
18. Visible light-mediated installation of halogen functionalities into multiple bond systems
Kim, H. J.*; Kim, M.*
17. Synthesis and molecular modeling studies of N'-Hydroxyindazolecarboximidamides as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor
Lee, D. H.; Lee, J. Y.; Jeong, J.; Kim, M.; Lee, K. W.; Jang, E.; Ahn, S.; Lee, C. H.*; Hwang, J. Y.*
16. Characterization and structure-activity relationship study of iminodipyridinopyrimidines as novel hepatitis C virus inhibito
Park, D. S.; Jo, E.; Choi, J.; Lee, M. E.; Kim, S.; Kim, H. Y.; Nam, J.; Ahn, S.; Hwang, J. Y.*; Windisch, M. P.*
15. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors
Park, S. J.; Kim, E.; Yoo, M.; Lee, J. Y.; Park, C. H.; Hwang, J. Y.*; Ha, J. D.*
14. Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor
Achary, R.; Mathi, G. R.; Lee, D. H.; Yun, C. S.; Lee, C. O.; Kim, H. R.; Park, C. H.; Kim, P. *; Hwang, J. Y.*
13. KRICT-9 inhibits neuroinflammation, amyloidogenesis and memory loss in Alzheimer’s disease models
Lee, D. Y.; Hwang, C. J.; Choi, J. Y.; Park, M. H.; Song, M. J.; Oh, K. W.; Han, S. B.; Park, W. K.; Cho, H. Y.; Cho, S. Y.; Park, H. B.; Song, M. J.; Hong, J. T.*
12. Design and Synthesis of Novel Pyrazolo[3,4-d]pyrimidin-1-yl piperidine Derivatives as Bruton’s Tyrosine Kinase Inhibitors
Park, H.; Park, C. H.; Kang, S. T.; Jeon, J. H.; Archary, R.; Lee, J. Y.; Kim, P.; Jung, H.; Yun, C. S.; Hwang, J. Y.; Ryu, D. H.; Cho, S. Y.*
11. Characterization of the aminopyridine derivatives KRC-180 as a JAK2 inhibitor
Yoon, K. Bin; Cho, S. Y.; An, S. J.; Park, K. R.; Lee, H. J.; Yoon, H. S.; Lee, S. M.; Kim, Y. C.; Han, S. Y.*
10. Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R
Mathi, G. R.; Kang, C. H.; Lee, H. K.; Achary, R.; Lee, H. Y.; Lee, J. Y.; Ha, J. D.; Ahn, S.; Park, C. H.; Lee, C. O.; Hwang, J. Y.; Yun, C. S.; Jung, H. J.; Cho, S. Y.; Kim, H. R.*; Kim, P.*
9. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors
Park, S. J.; Kim, E.; Yoo, M.; Lee, J.; Park, C. H.; Hwang, J. Y.*; Ha, J. D.*
8. Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies
Song, D.; Lee, M.; Park, C. H.; Ahn, S.; Yun, C. S.; Lee, C. O.; Kim, H. R.*; Hwang, J. Y.*
7. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer
Kang, C. H.; Kim, E. Y.; Kim, H. R.; Lee, C. O.; Lee, H. K.; Jeong, H. G.; Choi, S. U.; Yun, C.-S.; Hwang, J. Y.; Lee, J. Y.; Son, Y. H.; Ahn, S.; Lee, B. H.; Jung, H.*; Park, C. H.*
6. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.
Park, C. H.; Cho, S. Y.; Ha, J. Du; Jung, H.; Kim, H. R.; Lee, C. O.; Jang, I. Y.; Chae, C. H.; Lee, H. K.; Choi, S. U.*
5. Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors
Kim, E.Y.; Kang, S.T.; Jung, H.; Park, C. H.; Yun, C. S.; Hwang, J. Y.; Byun, B. J.; Lee, C. O.; Kim, H. R.; Ha, J. Du; Ryu, D. H.; Cho, S. Y.*
4. Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors
Achary, R.; Yun, J. I.; Park, C. M.; Mathi, G. R.; Lee, J. Y.; Ha, J. D.; Chae, C. H.; Ahn, S.; Park, C. H.; Lee, C. O.; Hwang, J. Y.; Yun, C.; Jung, H. J.; Cho, S. Y.; Kim, H. R.; Kim, P.*
3. Design, synthesis, and evaluation of 2,4-di(piperidine-substituted-anilino)pyrimidine derivatives as ALK inhibitors
Yun, J. I.; Jung, H. J.; Hwang, J. Y.; Park, C. H.; Ahn, S.; Kim, H. R.*
2. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins
Kang, C. H.; Yun, J. I.; Lee, K.; O. L. Chong.; Lee, H. K.; Chang-Soo,Y.; Hwang, J. Y.; Cho S. Y.; Jung, H.;Kim, P.; Ha, J. D.; Jeon, J. H.; Choi, S. U.; Jeong, H. G.; Kim, H. R.; Park, C. H.*
1. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor
Kang, G. A.; Lee, M.; Song, D.; Lee, H. K.; Ahn, S.; Park, C. H.; Lee, C. O.; Yun, C. S.; Jung, H.; Kim, P.; Ha, J. D.; Cho, S. Y.; Kim, H. R.*; Hwang, J. Y.*